The study funded by Sanofi shows that 30 percent of the insulin-dependent patients of type 2 diabetes (to control high blood sugar levels) does not start insulin therapy when physicians advise them. On an average, patients with diabetes are delaying the start of the treatment by about two years and by the time the blood glucose levels may further increase.
Researchers have examined the electronic medical records of 3,295 patients of diabetes between 2000 and 2014 at the Brigham and Women's Hospital, Boston, Massachusetts, United States. Their study shows that nearly one-third of the patients did not start the insulin injection therapy when physicians advise them. Patients are delaying the start of insulin treatment because.
Senior author of the study was Dr. Alexander Turchin, MD, MS, Associate Professor, Harvard Medical School, Boston, United States. The study was published on September 14, 2017, in Diabetic Medicine. Title of the article was "Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus."
About 25 percent of the patients of diabetes were affected by the disorders or damages from diabetic nerve pain, affecting the body including the arms, hands, feet and legs. The normal pain-relieving drugs may not provide relief to nerve pain because the pain in the sensory nerves is caused due to high blood sugar (glucose) levels (type 2 diabetes. T2D). Currently, there is no effective treatment for diabetic nerve pain.
A study by the researchers at the King's College London, United Kingdom, confirms the role of hyperpolarization-activated cyclic nucleotide- gated 2 (HCN2) gene or protein in the development of chronic diabetic nerve pain.
The researchers have conducted experiments on diabetic mice models. They found that overactive HCN2 gene can promote the pain or a burning sensation by inducing and maintaining electrical signals in nociceptive (a receptor) neurons. The researchers are successful in stopping the sensation of the nerve pain by "genetically deleting" or blocking HCN2 gene channels in the nociceptive (a receptor) neurons.
Currently, there are drugs with a selective mechanism to suppress the activity of HCN2 protein without affecting other organs (for example heart rate regulation). The researchers say that the painful diabetic neuropathy or chronic nerve pain may be treated by developing new drugs which can selectively target the HCN2 gene without disturbing other molecules.
The first author of the study was Dr. Christoforos Tsantoulas, Department of Pharmacology, King's College London. The senior author of the study was Professor Peter McNaughton, Wolfson Centre for Age-Related Diseases, King's College London, United Kingdom. The study was published on September 27, 2017, in the journal Science Translational Medicine. Title of the article was "Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.